Accepted Manuscript

Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment

Niwanthi W. Rajapakse, Shane Nanayakkara, David M. Kaye

PII: S0163-7258(15)00102-3

DOI: doi: 10.1016/j.pharmthera.2015.05.011

Reference: JPT 6786

To appear in: Pharmacology and Therapeutics



Please cite this article as: Rajapakse, N.W., Nanayakkara, S. & Kaye, D.M., Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment, *Pharmacology and Therapeutics* (2015), doi: 10.1016/j.pharmthera.2015.05.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

P&T # 22711

Pathogenesis and treatment of the cardiorenal syndrome:

Implications of L-arginine-nitric oxide pathway impairment

Niwanthi W. Rajapakse^{1,2}, Shane Nanayakkara³ and David M. Kaye^{1,3,4}

Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia¹; Department of Physiology, Monash University²; Department of Medicine, Monash University, Melbourne Australia³ and Department of Cardiovascular Medicine, Alfred Hospital⁴, Melbourne, Australia.

Corresponding author:

Dr Niwanthi Rajapakse,
Heart Failure Research Group,
Baker IDI Heart and Diabetes Institute,
75, Commercial Road, Melbourne, 3004,
Australia.

Phone: 613 8532 1583

Download English Version:

https://daneshyari.com/en/article/5843924

Download Persian Version:

https://daneshyari.com/article/5843924

<u>Daneshyari.com</u>